楚天科技(300358) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for the current period is ¥1,553,392,936.78, representing a 13.49% increase compared to the same period last year[3] - Net profit attributable to shareholders for the current period is ¥133,378,983.03, a 3.86% increase year-over-year[3] - Net profit for the current period was ¥134,572,400.59, representing a 6.5% increase from ¥126,109,671.27 in the previous period[31] - The total profit for the current period was ¥147,064,715.14, an increase of 7.5% from ¥136,612,669.18 in the last period[31] - The total comprehensive income for the current period was ¥144,762,047.17, compared to ¥103,214,262.13 in the previous period, marking a substantial increase[31] Cash Flow - The net cash flow from operating activities improved by 47.79%, reaching -¥331,395,404.12 compared to -¥634,793,368.16 in the previous year[3] - The net cash flow from operating activities for the current period was -331,395,404.12, an improvement from -634,793,368.16 in the previous period, indicating a reduction in cash outflow[15] - Cash inflow from operating activities totaled 1,643,073,589.40, compared to 1,408,088,107.11 in the previous period, reflecting a year-over-year increase of approximately 16.7%[15] - Cash outflow from operating activities decreased to 1,974,468,993.52 from 2,042,881,475.27, showing a reduction of about 3.3%[15] - The net cash flow from investing activities was -165,221,647.72, an improvement from -239,159,561.23 in the previous period[15] - Cash inflow from investing activities decreased significantly to 57,071,027.65 from 1,028,578,035.06, indicating a decline of approximately 94.5%[15] - Cash outflow from investing activities also decreased to 222,292,675.37 from 1,267,737,596.29, reflecting a reduction of about 82.5%[15] - The net cash flow from financing activities increased to 152,918,110.42 from 109,998,158.76, representing a growth of approximately 39%[17] Assets and Liabilities - The total assets at the end of the current period are ¥10,816,725,455.99, a decrease of 2.09% from the end of the previous year[3] - Total liabilities decreased to 6,360,976,921.31 from 6,751,469,493.90, indicating a reduction of about 5.8%[26] - The total equity increased to 4,455,748,534.68 from 4,296,041,389.28, reflecting an increase of approximately 3.7%[26] - The company's equity attributable to shareholders increased by 3.61% to ¥4,365,776,962.67 compared to the previous year[3] Expenses - Total operating costs amounted to ¥1,394,152,500.76, up 14.2% from ¥1,221,046,192.81 in the prior period[29] - Research and development expenses increased to ¥117,069,572.72, up 22% from ¥96,075,455.10 in the previous period[29] - Financial expenses rose by 635.02% to ¥12,537,900.00, primarily due to increased foreign exchange losses and interest expenses[6] - The company reported a significant increase in financial expenses, which rose to ¥14,512,288.23 from ¥1,974,401.31 in the previous period[29] Shareholder Information - Total number of common shareholders at the end of the reporting period is 19,889[38] - The largest shareholder, Changsha Chutian Investment Group Co., Ltd., holds 38.96% of shares, totaling 224,049,214 shares[38] Government and Other Income - The company received government subsidies amounting to ¥8,573,087.30, which are closely related to its normal business operations[9] - Other comprehensive income after tax was ¥10,189,646.58, a recovery from a loss of ¥22,895,409.14 in the previous period[31] - Investment income decreased by 3.51 million RMB, a decline of 131.53%, primarily due to losses from an associated company and reduced returns from financial products[51] - Asset disposal income increased by 1.67 million RMB, a growth of 2261.58%, due to the disposal of fixed assets by Romaco Tecpharm, S.L.[51] Future Plans - The company plans to issue convertible bonds not exceeding 1.1 billion for projects related to bioengineering and medical equipment, as well as to supplement working capital[19] - The company is undergoing a merger and acquisition review process, with the Shenzhen Stock Exchange confirming that the transaction meets restructuring conditions[13] Miscellaneous - The report confirms that the financial information is true, accurate, and complete[44] - The first quarter report has not been audited[52] - The total number of restricted shares at the beginning of the period was 58,120,691, with no shares released during the reporting period[41] - The company has no other significant non-recurring gains or losses to report[54] - Other equity instrument investments increased by 3 million yuan, a growth of 1337.37%, mainly due to the investment payment for the Changsha Jingji Biomedical Industry Investment Partnership project during the reporting period[55]